Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1403 | Pituitary Clinical | ICEECE2012

Pregnancies in a large cohort of patients on growth hormone replacement therapy

Vila G , Akerblad A. , Biller B. , Koltowska-Haggstrom M. , Lundgren F. , Riedl M. , Luger A.

Introduction: Growth hormone replacement (GHRT) during conception and pregnancy is an off-label treatment. Reports on pregnancy outcomes in women with growth hormone deficiency (GHD) are derived from single center studies with small sample sizes and show conflicting results.Methods/design: We evaluate pregnancies reported in the KIMS (Pfizer International Metabolic Database) patients on GHRT. KIMS includes 4651 women aged 15–50 years (followed for 1...

ea0029oc1.2 | Pituitary Clinical I | ICEECE2012

Patients with Cushing’s disease achieve normal urinary cortisol with LCI699, a potent 11β-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study

Bertagna X. , Pivonello R. , Fleseriu M. , Zhang Y. , Robinson P. , Taylor A. , Watson C. , Maldonado M. , Hamrahian A. , Boscaro M. , Biller B.

Introduction: The clinical features and complications of Cushing’s syndrome result from chronic excess of circulating cortisol, typically quantified by 24-h urinary free cortisol (UFC). LCI699 is a potent inhibitor of 11β-hydroxylase. Since 11β-hydroxylase catalyzes the final step of cortisol synthesis, LCI699 is a potential new treatment for all forms of Cushing’s syndrome.Methods: Adult patients with mild-to-severe Cushing’s di...

ea0029p1406 | Pituitary Clinical | ICEECE2012

Pasireotide treatment is associated with improvements in hypertension: 12-month results from a large phase III study in Cushing’s disease

Pivonello R , Petersenn S , Newell-Price J , Gu F , Maldonado M , Trovato A , Hughes G , Salgado L , Lacroix A , Schopohl J , Biller B

Introduction: Patients with Cushing’s disease (CD) have an increased risk of hypertension (HTN). phase III data have shown that pasireotide leads to rapid reductions in UFC levels and significant improvements in CD symptoms. We now present further analyses of these data, evaluating the effects of pasireotide on HTN in patients with CD.Methods: Patients with persistent/recurrent or de novo (if not surgical candidates) CD and UFC≥1.5 time...

ea0026p265 | Pituitary | ECE2011

Pasireotide (SOM230) demonstrates efficacy in patients with Cushing’s disease: results from a large, randomized-dose, double-blind, Phase III study

Colao A , Petersenn S , Newell-Price J , Findling J W , Gu F , Maldonado M , Schoenherr U , Mills D , Salgado L R , Biller B M K

Introduction: Pasireotide is a multi-receptor targeted somatostatin analogue with high affinity for sst5, which is commonly expressed in corticotroph adenomas, thus having potential as therapy for Cushing’s disease.Methods: One hundred and sixty-two patients with persistent/recurrent or de novo (if not surgical candidates) Cushing’s disease were randomized (double-blind) to pasireotide 600 μg (n=82) or 900 μg ...

ea0026p284 | Pituitary | ECE2011

Improvement in clinical signs and symptoms of Cushing’s disease following 12 months' pasireotide therapy

Pivonello R , Newell-Price J , Findling J W , Gu F , Maldonado M , Schoenherr U , Mills D , Salgado L R , Biller B M K

Introduction: The multi-receptor targeted somatostatin analogue pasireotide has demonstrated efficacy in reducing cortisol in patients with Cushing’s disease in a large, randomized, double-blind, Phase III study. The effects of pasireotide on the signs and symptoms of Cushing’s disease were also investigated as secondary objectives in this trial.Methods: Adult patients with persistent/recurrent or de novo Cushing’s disease were rand...

ea0026p216 | Pituitary | ECE2011

Long-term treatment of acromegaly with pegvisomant (Somavert): cross-sectional observations from ACROSTUDY, a post-marketing, international, safety, surveillance study

van der Lely A J , Lundgren F , Biller B M K , Brue T , Cara J , Ghigo E , Hadavi J Hey , Rajicic N , Saller Bernhard , Sanocki John , Strasburger Christian , Webb Susan , Haggstrom Maria Koltowska

Introduction: Somavert is a GH receptor blocker, which inhibits hepatic production of IGF1. While it has been approved for the treatment of acromegaly since 2003 there are few data regarding its effects in everyday clinical practice.Methods/design: ACROSTUDY is an open-label, international, prospective, non-interventional, post-marketing surveillance study monitoring the long-term safety and efficacy of Somavert.Results: As of Dece...